• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 2 - Genetics and Next-Generation Sequencing

Article

Dr Kumar continues his analysis of the genetic and familial probability of a patient being diagnosed with multiple myeloma.

Dr Kumar continues his analysis of the genetic and familial probability of a patient being diagnosed with multiple myeloma.

Dr Chernew questions the value of circulating plasma cells as independent prognostic markers in newly diagnosed multiple myeloma, as well as circulating serum microRNAs for diagnosis of multiple myeloma.

The panelists then discuss next-generation sequencing, deep sequencing, and ASO-qPCR in detecting minimal residual disease (MRD). Dr Kumar says there is a growing interest in MRD and explains all the emerging developments for detection of MRD.

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.